Management of erectile dysfunction post-radical prostatectomy.
Radical prostatectomy is a commonly performed procedure for the treatment of localized prostate cancer. One of the long-term complications is erectile dysfunction. There is little consensus on the optimal management; however, it is agreed that treatment must be prompt to prevent fibrosis and increase oxygenation of penile tissue. It is vital that patient expectations are discussed, a realistic time frame of treatment provided, and treatment started as close to the prostatectomy as possible. Current treatment regimens rely on phosphodiesterase 5 inhibitors as a first-line therapy, with vacuum erection devices and intraurethral suppositories of alprostadil as possible treatment combination options. With nonresponders to these therapies, intracavernosal injections are resorted to. As a final measure, patients undergo the highly invasive penile prosthesis implantation. There is no uniform, objective treatment program for erectile dysfunction post-radical prostatectomy. Management plans are based on poorly conducted and often underpowered studies in combination with physician and patient preferences. They involve the aforementioned drugs and treatment methods in different sequences and doses. Prospective treatments include dietary supplements and gene therapy, which have shown promise with there proposed mechanisms of improving erectile function but are yet to be applied successfully in human patients.
Division of Surgery and Cancer, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.
Alan
A
Saleh
Division of Surgery and Cancer, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.
Hamid
H
Abboudi
Division of Surgery and Cancer, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.
Mb
M
Ghazal-Aswad
Division of Surgery and Cancer, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.
Erik K
EK
Mayer
Division of Surgery and Cancer, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.
Justin A
JA
Vale
erectile dysfunction; intracavernosal injections; intraurethral suppositories; phosphodiesterase 5 inhibitors; vacuum erection devices